Parkinson's new drug! Sumitomo pharmaceutical's new apomorphine sublingual membrane agent apl-130277 has entered the review in the United States, rapidly treating various off events on demand
Time of Update: 2019-12-28
December 27, 2019 / Biovalley bio on / -- Sumitomo Pharma, a US subsidiary of Sumitomo pharmaceutical, recently announced that the US Food and Drug Administration (FDA) has
Parkinson's new drug! Kirin nourianz (Istra defylline) is listed in the United States for treatment of off events
Time of Update: 2019-10-16
As an additional treatment of levodopa / carbidopa, it is used for adult patients with Parkinson's disease (PD) who are experiencing the "off" event.
[Yao Kejun] drug review trends: new drugs and rare disease drugs urgently needed in clinical practice are accepted; Parkinson's disease innovative therapy is listed in the United States; Xiehe Kirin, Bayer, Hengrui, Renfu
Time of Update: 2019-09-02
In response to the urgent needs of patients for new drug-resistant antibiotics, in September 2003, the U.S. FDA approved for the first time the use of daptomycin for injection (trade name: Cubicin ®) through the priority approval process.
Good news for Chinese Parkinson patients! Youshibi neupro (rotigotine patch) approved by China
Time of Update: 2018-07-05
With the approval of neupro in China, we are happy to bring this drug to millions of Parkinson's patients, and provide them with a convenient treatment plan to help them manage their condition.
Another new Parkinson's disease drug approved by FDA
Time of Update: 2017-08-28
Source: the US FDA approved the new drug gocovri (amantadine, amantadine, formerly ads-5102) sustained-release capsule of adamas pharmaceuticals for the treatment of movement disorders in Parkinson's disease patients receiving levodopa treatment recently.
In half a year, heavy new drugs appear frequently, and nervous system diseases are frequently used
Time of Update: 2017-08-14
With the deepening of social aging, the incidence rate of neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease is also increasing
Tianbian Mitsubishi's $1.1 billion acquisition of neuroderm as Parkinson's potential drug
Time of Update: 2017-07-25
Source: Sina Pharmaceutical News on July 25, 2017, Mitsubishi Tanabe Pharma, a Japanese pharmaceutical company, recently announced that it had signed a $1.1 billion acquisition
FDA approved the first new Parkinson's disease drug in ten years
Time of Update: 2017-03-22
FDA announced that xadago (safinamide), a new Parkinson's disease drug developed by newron pharmaceuticals, has been approved for marketing as an additional therapy in addition to levodopa / carbidopa treatment.
Boost enterprise confidence adjustment of export tax rebate rate of pharmaceutical products
Time of Update: 2015-02-03
The varieties of the tax rebate rate adjustment have the characteristics of high added value, international competitiveness and low energy consumption, which play a leading role in export orientation and boost the confidence of pharmaceutical enterprises in foreign trade.
CDE drug review weekly report (2015.1.19-1.25
Time of Update: 2015-01-26
For hydromorphone hydrochloride sustained-release tablets, there is no listing, only two enterprises apply, namely Johnson & Johnson and Qinghai pharmaceutical factory.